180 related articles for article (PubMed ID: 16078135)
21. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.
Storch CH; Theile D; Lindenmaier H; Haefeli WE; Weiss J
Biochem Pharmacol; 2007 May; 73(10):1573-81. PubMed ID: 17328866
[TBL] [Abstract][Full Text] [Related]
22. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.
Eilers M; Roy U; Mondal D
Exp Biol Med (Maywood); 2008 Sep; 233(9):1149-60. PubMed ID: 18535159
[TBL] [Abstract][Full Text] [Related]
23. Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model.
Shibata N; Gao W; Okamoto H; Kishida T; Iwasaki K; Yoshikawa Y; Takada K
J Pharm Sci; 2002 Mar; 91(3):680-9. PubMed ID: 11920753
[TBL] [Abstract][Full Text] [Related]
24. Effects of HIV-1 Tat and Methamphetamine on Blood-Brain Barrier Integrity and Function
Patel S; Leibrand CR; Palasuberniam P; Couraud PO; Weksler B; Jahr FM; McClay JL; Hauser KF; McRae M
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893794
[TBL] [Abstract][Full Text] [Related]
25. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).
Olson DP; Scadden DT; D'Aquila RT; De Pasquale MP
AIDS; 2002 Sep; 16(13):1743-7. PubMed ID: 12218384
[TBL] [Abstract][Full Text] [Related]
26. Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.
Richter M; Gyémánt N; Molnár J; Hilgeroth A
Pharm Res; 2004 Oct; 21(10):1862-6. PubMed ID: 15553233
[TBL] [Abstract][Full Text] [Related]
27. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
[TBL] [Abstract][Full Text] [Related]
28. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers.
Fontaine M; Elmquist WF; Miller DW
Life Sci; 1996; 59(18):1521-31. PubMed ID: 8890933
[TBL] [Abstract][Full Text] [Related]
29. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.
Ford J; Meaden ER; Hoggard PG; Dalton M; Newton P; Williams I; Khoo SH; Back DJ
J Antimicrob Chemother; 2003 Sep; 52(3):354-8. PubMed ID: 12917239
[TBL] [Abstract][Full Text] [Related]
30. Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.
Shaik N; Pan G; Elmquist WF
J Pharm Sci; 2008 Dec; 97(12):5421-33. PubMed ID: 18393290
[TBL] [Abstract][Full Text] [Related]
31. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.
Ye ZW; Camus S; Augustijns P; Annaert P
Biopharm Drug Dispos; 2010 Mar; 31(2-3):178-88. PubMed ID: 20238377
[TBL] [Abstract][Full Text] [Related]
32. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid.
Kaddoumi A; Choi SU; Kinman L; Whittington D; Tsai CC; Ho RJ; Anderson BD; Unadkat JD
Drug Metab Dispos; 2007 Sep; 35(9):1459-62. PubMed ID: 17591677
[TBL] [Abstract][Full Text] [Related]
34. Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.
Roy U; Chakravarty G; Honer Zu Bentrup K; Mondal D
Biol Pharm Bull; 2009 Dec; 32(12):2002-9. PubMed ID: 19952419
[TBL] [Abstract][Full Text] [Related]
35. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes.
Nakagawa S; Deli MA; Kawaguchi H; Shimizudani T; Shimono T; Kittel A; Tanaka K; Niwa M
Neurochem Int; 2009; 54(3-4):253-63. PubMed ID: 19111869
[TBL] [Abstract][Full Text] [Related]
36. Specific increase in MDR1 mediated drug-efflux in human brain endothelial cells following co-exposure to HIV-1 and saquinavir.
Roy U; Bulot C; Honer zu Bentrup K; Mondal D
PLoS One; 2013; 8(10):e75374. PubMed ID: 24098380
[TBL] [Abstract][Full Text] [Related]
37. Nicotine and cotinine increases the brain penetration of saquinavir in rat.
Manda VK; Mittapalli RK; Bohn KA; Adkins CE; Lockman PR
J Neurochem; 2010 Dec; 115(6):1495-507. PubMed ID: 20950334
[TBL] [Abstract][Full Text] [Related]
38. Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport.
Gibbs JP; Adeyeye MC; Yang Z; Shen DD
Epilepsy Res; 2004 Jan; 58(1):53-66. PubMed ID: 15066675
[TBL] [Abstract][Full Text] [Related]
39. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.
Janneh O; Owen A; Chandler B; Hartkoorn RC; Hart CA; Bray PG; Ward SA; Back DJ; Khoo SH
AIDS; 2005 Dec; 19(18):2097-102. PubMed ID: 16284458
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.
Janneh O; Jones E; Chandler B; Owen A; Khoo SH
J Antimicrob Chemother; 2007 Nov; 60(5):987-93. PubMed ID: 17890284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
